Clinical Trial Update: A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis [Phase 4]

View source ↗

Summary

A Phase 4 study evaluating deucravacitinib for palmoplantar and genital psoriasis was terminated, with study results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Genital Psoriasis
• Palmoplantar Psoriasis

Drugs mentioned

• Deucravacitinib (deucravacitinib)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Palmoplantar Psoriasis, Genital Psoriasis | Phase 4 | Status: TERMINATED | Results posted: 2026-04-17